Ingelheim, Germany

Arne Froemder

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2013.


% Patents Active = 100.0



Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Arne Froemder: Innovator in Aerosol Suspension Formulations

Introduction

Arne Froemder is a notable inventor based in Ingelheim, Germany. He has made significant contributions to the field of aerosol suspension formulations. His innovative work has led to the development of a unique patent that addresses the use of specific propellants in aerosol products.

Latest Patents

Froemder holds a patent for "Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant." This patent discloses propellant gas formulations that contain at least one suspended active substance, which includes chemically bound water, water, and the propellant TG 227 or TG 134 a. This formulation is crucial for enhancing the efficacy and stability of aerosol products.

Career Highlights

Throughout his career, Arne Froemder has worked with prominent companies in the pharmaceutical industry. He has been associated with Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharma GmbH & Co. KG. His experience in these organizations has allowed him to refine his expertise in aerosol technologies and formulations.

Collaborations

Froemder has collaborated with various professionals in his field, including his coworker Christel Schmelzer. These collaborations have contributed to the advancement of aerosol formulation technologies.

Conclusion

Arne Froemder's innovative work in aerosol suspension formulations has made a significant impact in the pharmaceutical industry. His patent and career achievements reflect his dedication to advancing aerosol technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…